New Rapid-acting Antidepressants

This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments. Discusses new candidate for rapid-acting antidepressants Provides information for those who work in the field of CNS drugs Ideal for pharmacologists, psychiatrists, and those who want to learnabout CNS drugs at the graduate level

Auteur

First Name Kenji
Last Name Hashimoto
Institution - Chiba University Center for Forensic Mental Health
Department - Division of Clinical Neuroscience
City Chiba 260-8670
State Chiba
Country Japan
Email hashimoto@faculty.chiba-u.jp

Kenji Hashimoto, PhD Chiba University, Chiba, Japan

Dr. Hashimoto is a professor and vice-director of Chiba University Center for Forensic Mental Health from 2005. Dr. Hashimoto graduated from Faculty of Pharmaceutical Sciences at Kyushu University, and received PhD. After Dr. Hashimoto worked at Fukuyama University, National Institutes of Health (NIH)/National Institute of Drug Addiction (NIDA)(Baltimore, MD, USA) and Pharmaceutical company, he moved at Chiba University Graduate School of Medicine from 2001. Dr. Hashimoto works on the development of novel therapeutic drugs for psychiatric and neurological disorders. Dr. Hashimoto published more than 550 articles in PubMed listed publications. Dr. Hashimoto focus on the molecular and cellular mechanisms of ketamine's antidepressant actions.

Texte du rabat
This book discusses new candidates for rapid-acting antidepressants, such as (R)-ketamine, (2R,6R)-hydroxynorketamine, scopolamine, mGluR2/3 antagonists and AMPA receptor agonists. There are serious limitations to currently available antidepressants, such as delayed onset and low rates of efficacy. The discovery that a single dose of ketamine, an NMDAR antagonist, can produce rapid antidepressant effects that are sustained has led to new research in this area. In this volume, a variety of novel pharmaceutical treatments are examined. This volume would be useful to both researchers and clinicians who work in the field of pharmacology, specifically CNS drug treatments.
Discusses new candidate for rapid-acting antidepressants
Provides information for those who work in the field of CNS drugs
Ideal for pharmacologists, psychiatrists, and those who want to learn about CNS drugs at the graduate level

Contenu
1) Esketamine (Janssen Pharmaceutical Ltd., USA)Ella J. Daly (edaly2@its.jnj.com) or Jaskaran B. Singh (jsingh25@its.jnj.com)
2) (R)-Ketamine:Kenji Hashimoto (Chiba University, Japan) e-mail: hashimoto@faculty.chiba-u.jp
3) (2R,6R)-HNK (metabolite of R-ketamine):Todd D. Gould (University of Maryland, USA) (gouldlab@me.com) or Panos Zanos (panoszanos1986@gmail.com)
4) Lanicemine and BHV-5000 (low-trapping NMDAR antagonist)Biohaven Pharmaceutical (http://biohavenpharma.com/)
5) Rapastinel and Apimostinel: (Naurex OR Allergan)Joseph R. Moskal (Northwestern University, USA)( j-moskal@northwestern.edu)
6) AV-101 (L-4-chlorokynurenine: NMDAR glycine site antagonist):VistaGen Therapeutics (https://www.vistagen.com/)
7) TAK-653 (AMPAR potentiator):Haruhide Kimura (Takeda Pharmaceutical Co., Ltd, Japan) e-mail: haruhide.kimura@takeda.com
8) mGluR2/3 antagonists:Shigeyuki Chaki (Taisho Pharmaceutical Co, Ltd, Japan) e-mail: s-chaki@taisho.co.jp
9) SAGE-217 PAM at GABA-A:Sage Therapeutics, Inc. USA (https://www.sagerx.com/)
10) NAM at alpha-5 GABA-A:Scott M. Thompson (University of Maryland, USA) e-mail: sthompson@som.umaryland.edu
11) Scopolamine (muscarinic AChR antagonist):Ronald S. Duman (Yale University, USA) e-mail: ronald.duman@yale.edu
12) Sirukumab (IL-6 antibody)(Janssen Pharmaceutical Co, Ltd)Roger S. McIntyre (University of Toronto: roger.mcintyre@uhn.ca)
13) Seltorexant (orexin-2 receptor antagonist):Janssen Pharmaceutical Ltd. (Peter De Boer: pdeboer1@jts.jmj.com) ORMinera Neuroscience Inc. (Remy Luthringer) (http://www.minervaneurosciences.com/)
14) JNJ-55308942 (P2X7 antagonist)Anindya Bhattacharya (J&J, abhatta2@its.jnj.com)
15) Psilocybin (psychedelic drug)Compass Pathway (https://compasspathways.com/)